Efficacy and safety of rituximab for patients with severe rheumatic disease
Not Applicable
- Conditions
- Childhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome)
- Registration Number
- JPRN-UMIN000018376
- Lead Sponsor
- Yokohama City University Hospital Department of Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2. Infection of HIV, HCV or HBV 3. Administraion of live vaccine within 4 weeks 4. Interstatial lung disease 5. Cardiac dysfunction 6. Pregnant subjects or subjects who do not agree with contraception during the study period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method inhibition of disease activity
- Secondary Outcome Measures
Name Time Method improvement of physician's VAS, patient's VAS, biomarkers of disease activity and dose of corticosteroids